Joseph M. Palumbo

January 9, 2023

Role of the endocannabinoid system in fragile X syndrome: potential mechanisms for benefit from cannabidiol treatment

Abstract Multiple lines of evidence suggest a central role for the endocannabinoid system (ECS) in the neuronal development and cognitive…

November 25, 2022

A randomized, controlled trial of ZYN002 cannabidiol transdermal gel in children and adolescents with fragile X syndrome (CONNECT-FX)

Abstract Background: Fragile X syndrome (FXS) is associated with dysregulated endocannabinoid signaling and may therefore respond to cannabidiol therapy. Design:…